MDP Multidose Kit
Several adverse reactions due to technetium Tc99m medronate have been reported. These were usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, chills, nausea and vomiting. There have also been rare cases of dizziness and asthenia associated with the use of technetium Tc99m medronate.
The following adverse reactions associated with the use of technetium Tc99m medronate have been identified during post-approval use:
Anaphylactic/anaphylactoid reactions that may be life-threatening and include shock, hypotension, loss of consciousness, dyspnea, cyanosis, and wheezing. Advanced life support equipment and trained personnel should be readily available.
Local or generalized rash with itching and dermal irritation, headache, malaise, edema of the extremities, and arthralgia have also been reported. The time to onset of these symptoms may occur within minutes or be delayed by several hours post-administration of technetium Tc99m medronate. Users are requested to report to GE Healthcare any instances of suspected adverse drug reactions associated with the use of technetium Tc99m medronate.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the MDP Multidose Kit (technetium tc99m medronate injection) Side Effects Center for a complete guide to possible side effects
No information provided.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/3/2007
Additional MDP Multidose Kit Information
Report Problems to the Food and Drug Administration
Find out what women really need.